On November 9, 2023, Revolution Medicines, Inc. (?Revolution Medicines?), completed the previously announced acquisition of EQRx, Inc. (?EQRx?), pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (the ?Merger Agreement?), by and among Revolution Medicines, Equinox Merger Sub I, Inc. and a direct, wholly owned subsidiary of Revolution Medicines (?Merger Sub I?), Equinox Merger Sub II LLC and a direct, wholly owned subsidiary of Revolution Medicines (?Merger Sub II?), and EQRx. Pursuant to the Merger Agreement, Merger Sub I merged with and into EQRx, with EQRx surviving as a wholly owned subsidiary of Revolution Medicines (the ?First Merger?), and following the First Merger, EQRx merged with and into Merger Sub II, with Merger Sub II surviving as a wholly owned subsidiary of Revolution Medicines with the name ?EQRx, LLC? (the ?Surviving Company?) (the ?Second Merger,?

and together with the First Merger, the ?Mergers?). Pursuant to the Merger Agreement, as of the Effective Time, Alexis Borisy, Amy Abernethy, M.D., Ph.D., Paul Berns, Jorge Conde, Kathryn Giusti, Sandra J. Horning, M.D., Clive Meanwell, M.B., Ch.B., M.D, Samuel Merksamer, Melanie Nallicheri, and Krishna Yeshwant, M.D. resigned from the board of directors of EQRx and any committees thereof and each of the named executive officers of EQRx ceased to be officers of EQRx and its subsidiaries.